| Drug General Information |
| Drug ID |
D0K3SM
|
| Former ID |
DIB010765
|
| Drug Name |
MALP-2S
|
| Indication |
Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10:C25]
|
Phase 1/2 |
[1]
|
|---|
| Company |
MBiotec GmbH
|
| Target and Pathway |
| Target(s) |
Toll-like receptor 6 |
Target Info |
Modulator |
[2]
|
|---|
| Toll-like receptor 2 |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Phagosome
|
|
Toll-like receptor signaling pathway
|
|
Chagas disease (American trypanosomiasis)
|
|
Tuberculosishsa04145:Phagosome
|
|
PI3K-Akt signaling pathway
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Malaria
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Measles
|
|
Herpes simplex infection
|
|
Proteoglycans in cancer
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
TCR Signaling PathwayNetPath_16:IL4 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Toll receptor signaling pathwayP00054:Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
Endogenous TLR signalingtoll_endogenous_pathway:Endogenous TLR signaling
|
|
Reactome
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Toll Like Receptor TLR6:TLR2 Cascade
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)R-HSA-1461957:Beta defensins
|
|
IRAK4 deficiency (TLR2/4)
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Toll-Like Receptors Cascades
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Regulation of toll-like receptor signaling pathwayWP75:Toll-like receptor signaling pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Human Complement System
|
|
Defensins
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer. 2007 Sep 3;97(5):598-604. Epub 2007 Jul 31. |
|---|
| REF 2 | Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8. |
|---|
